 NEW YORK, Oct. 8, 2019 PRNewswire -- Neurotrope, Inc. NTRP, a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, today announced its plans to explore strategic alternatives to maximize shareholder value. Following the results from our Phase 2 study of Bryostatin-1 in Alzheimers disease, we believe a review of strategic alternatives is an important step toward preserving and enhancing shareholder value, stated Dr. Charles S. Ryan, Neurotropes Chief Executive Officer. There can be no assurance that the formal strategic review of alternatives will result in any successful transaction or other outcome. 